BHCM
ABOS icon

Brevan Howard Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Brevan Howard Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.3K Buy
+15,385
New +$39.2K ﹤0.01% 2104
2024
Q2 		– Sell
-56,369
Closed -$228K – 1023
2024
Q1 		$228K Buy
+56,369
New +$212K ﹤0.01% 750

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Brevan Howard Capital Management's ABOS Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 15,385 shares worth $36.3K. The stake represents ﹤0.01% of the portfolio and ranks #2104 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in ABOS as recently as Q1 2024.

Brevan Howard Capital Management first reported a position in ABOS in Q1 2024 and has held it in 2 quarters since. The position peaked at $228K in Q1 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Brevan Howard Capital Management held 15,385 shares of Acumen Pharmaceuticals worth $36.3K as of Q1 2026.
  • Acumen Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #2104 holding.
  • Brevan Howard Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Acumen Pharmaceuticals position peaked at $228K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.